{"id":"somatostatin-or-terlipressin","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Cardiac arrhythmias"},{"rate":null,"effect":"Ischemic complications"}]},"_chembl":{"chemblId":"CHEMBL2135460","moleculeType":"Protein","molecularWeight":"1227.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Somatostatin is a naturally occurring inhibitory peptide that binds to somatostatin receptors (SSTR1-5) on vascular smooth muscle and endothelial cells, causing vasoconstriction of splanchnic vessels and reducing portal venous inflow. Terlipressin is a selective vasopressin V1 receptor agonist that causes systemic and splanchnic vasoconstriction, increasing systemic vascular resistance and reducing portal pressure. Both agents are used acutely to control variceal bleeding by decreasing portal hypertension.","oneSentence":"Somatostatin and terlipressin are vasoactive peptides that bind to somatostatin receptors and vasopressin receptors respectively, reducing splanchnic blood flow and portal pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:46.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute variceal bleeding in portal hypertension"},{"name":"Prevention of variceal rebleeding"}]},"trialDetails":[{"nctId":"NCT06122792","phase":"NA","title":"Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-01","conditions":"Portal Hypertension, Gastric Varices Bleeding, Portosystemic Shunt","enrollment":144},{"nctId":"NCT06122753","phase":"NA","title":"Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-01","conditions":"Portal Hypertension, Portal Vein Thrombosis, Esophageal Varix Bleeding","enrollment":120},{"nctId":"NCT03846180","phase":"","title":"Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2019-03-01","conditions":"Variceal Hemorrhage, Cirrhosis, Liver, Kidney Injury","enrollment":1682},{"nctId":"NCT01370161","phase":"NA","title":"Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2011-07","conditions":"Decompensated Cirrhosis, Bleeding Varices","enrollment":132},{"nctId":"NCT02364297","phase":"NA","title":"TIPS in Fundal Variceal Bleeding (the TFB Study)","status":"UNKNOWN","sponsor":"Institut d'Investigacions Biomèdiques August Pi i Sunyer","startDate":"2015-09","conditions":"Portal Hypertension, Bleeding Gastric Varices","enrollment":60},{"nctId":"NCT02757703","phase":"PHASE4","title":"Vasoactive Drugs in Real World Practice","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2010-05","conditions":"Vasoconstrictor Choice on Acute Variceal Bleeding","enrollment":150},{"nctId":"NCT02311608","phase":"","title":"Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2014-02","conditions":"Liver Cirrhosis, Esophageal and Gastric Varices, Hemorrhage","enrollment":1320},{"nctId":"NCT01112852","phase":"PHASE4","title":"EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding","status":"COMPLETED","sponsor":"National Science and Technology Council, Taiwan","startDate":"2006-12","conditions":"Esophageal Varices, Bleeding","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["somatostatin and terlipressin are vasoconstrictors."],"phase":"marketed","status":"active","brandName":"somatostatin or terlipressin","genericName":"somatostatin or terlipressin","companyName":"National Science and Technology Council, Taiwan","companyId":"national-science-and-technology-council-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Somatostatin and terlipressin are vasoactive peptides that bind to somatostatin receptors and vasopressin receptors respectively, reducing splanchnic blood flow and portal pressure. Used for Acute variceal bleeding in portal hypertension, Prevention of variceal rebleeding.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}